Effective January 20, 2026, Cencora has elected Ellen Cooper—Chairman, President and CEO of Lincoln Financial—as an independent director. Cooper brings more than two decades of leadership in regulated industries, having served as EVP and Chief Investment Officer at Lincoln Financial, Managing Director and Global Head of Insurance Strategy at Goldman Sachs Asset Management, and Chief Risk Officer for AEGON Americas. Her credentials include a Bachelor of Business Administration from Temple University, Fellowship in the Society of Actuaries, and Chartered Financial Analyst designation. Board Chair Mark Durcan highlighted her risk management acumen as critical to guiding Cencora’s growth trajectory. Cencora, ranked #10 on the Fortune 500 with over $300 billion in annual revenue and a workforce exceeding 51,000 globally, stands to benefit from Cooper’s strategic perspective as it navigates complex regulatory environments and expands its pharmaceutical solutions platform.

Cencora has entered into a strategic collaboration with Curant Rare, a business unit of Curant Health, to provide an integrated commercialization and logistics solution for rare and orphan disease therapies. Leveraging Cencora’s global pharmaceutical logistics network and pharmacovigilance expertise alongside Curant Rare’s specialty pharmacy services and omnichannel patient engagement platform, the partnership aims to streamline market access, reduce time-to-therapy, and improve patient adherence. Investors should note that the collaboration targets the fast-growing orphan drug sector—where global market spend is projected to exceed $250 billion by 2028—by addressing high-cost, low-volume distribution challenges and complex regulatory requirements. Patrick Dunham, CEO of Curant Health, projects this integrated model will drive double-digit revenue growth in specialty services for both organizations over the next three years.